Rep. Gilbert Ray Cisneros, Jr. Sells Off Shares of Boston Scientific Corporation (NYSE:BSX)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Boston Scientific Corporation (NYSE:BSX). In a filing disclosed on January 12th, the Representative disclosed that they had sold between $1,001 and $15,000 in Boston Scientific stock on December 24th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Xiaomi (OTCMKTS:XIACF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Schneider Electric S.E. (OTCMKTS:SBGSF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Hermès International Société en commandite par actions (OTCMKTS:HESAF) on 12/30/2025.
• Purchased $50,001 – $100,000 in shares of Campbell’s (NASDAQ:CPB) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Tencent (OTC:TCTZF) on 12/30/2025.
• Sold $1,001 – $15,000 in shares of Mitsubishi Heavy Industries (OTCMKTS:MHVYF) on 12/26/2025.
• Sold $1,001 – $15,000 in shares of Bloom Energy (NYSE:BE) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Arista Networks (NYSE:ANET) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Coinbase Global (NASDAQ:COIN) on 12/24/2025.
• Sold $1,001 – $15,000 in shares of Chevron (NYSE:CVX) on 12/24/2025.

Boston Scientific Stock Down 0.5%

NYSE:BSX traded down $0.45 during midday trading on Wednesday, reaching $93.69. 7,270,235 shares of the stock traded hands, compared to its average volume of 7,309,612. The stock has a market capitalization of $138.89 billion, a PE ratio of 50.10, a price-to-earnings-growth ratio of 1.67 and a beta of 0.67. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. The business has a 50-day moving average of $97.32 and a two-hundred day moving average of $100.53.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same period in the prior year, the firm posted $0.63 earnings per share. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Boston Scientific

Hedge funds have recently bought and sold shares of the stock. Brighton Jones LLC increased its holdings in Boston Scientific by 0.8% in the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares in the last quarter. Geneos Wealth Management Inc. grew its position in shares of Boston Scientific by 136.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 3,423 shares of the medical equipment provider’s stock valued at $345,000 after acquiring an additional 1,977 shares during the period. Advisors Capital Management LLC increased its stake in shares of Boston Scientific by 27.5% in the 1st quarter. Advisors Capital Management LLC now owns 4,400 shares of the medical equipment provider’s stock valued at $444,000 after purchasing an additional 948 shares in the last quarter. Modern Wealth Management LLC grew its holdings in Boston Scientific by 7.9% in the first quarter. Modern Wealth Management LLC now owns 2,974 shares of the medical equipment provider’s stock valued at $300,000 after purchasing an additional 218 shares during the period. Finally, Kera Capital Partners Inc. purchased a new stake in shares of Boston Scientific in the second quarter valued at approximately $354,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director directly owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 93,095 shares of company stock valued at $9,305,450 in the last three months. 0.50% of the stock is currently owned by company insiders.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA clearance for the Farapoint pulsed-field ablation (PFA) catheter expands Boston Scientific’s electrophysiology (EP) portfolio and supports the company’s stated expectation for strong PFA performance in 2026 and beyond — a revenue catalyst for its cardiac rhythm business. Boston Scientific wins FDA nod for Farapoint PFA catheter
• Positive Sentiment: CE mark granted for the Embold detachable coil system broadens access to a neurovascular product in international markets, supporting incremental sales outside the U.S. and adding to higher-margin product mix. Boston Scientific wins CE mark for Embold detachable coil system
• Positive Sentiment: Boston Scientific agreed to acquire Valencia Technologies to bolster its pelvic health/urology portfolio — a strategic tuck-in that accelerates growth in a high-margin, underpenetrated segment and was highlighted by multiple analysts as supporting upside. Boston Scientific to buy incontinence device maker Valencia
• Positive Sentiment: Major sell-side analysts reiterated Buy ratings and upbeat commentary (Stifel, Citi, Bank of America), citing diversified growth engines (EP, neuro, urology/pelvic health), strong execution and the new product/market approvals as reasons to maintain upside targets. Boston Scientific: Diversified Growth Engines and Strong Execution Underpin Reiterated Buy Rating
• Neutral Sentiment: Local expansion: Boston Scientific plans a manufacturing/operations expansion in Maple Grove, which supports capacity for new products but may require near-term capital spend. Boston Scientific plans expansion in Maple Grove
• Neutral Sentiment: Company presented at the J.P. Morgan Healthcare Conference — the transcript highlights management’s strategy, guidance and product rollout cadence but contained no surprise items beyond already announced approvals/acquisitions. Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Analyst commentary and sector pieces note BSX benefits from a favorable product mix shift toward higher-margin devices, supporting medium-term margin improvement but not an immediate earnings surprise. 3 MedTech Stocks Benefiting From Favorable Product Mix Shifts

Analysts Set New Price Targets

A number of research firms have commented on BSX. Weiss Ratings reiterated a “buy (b-)” rating on shares of Boston Scientific in a research note on Wednesday, October 8th. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Barclays increased their price objective on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Robert W. Baird raised their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Finally, Cowen reiterated a “buy” rating on shares of Boston Scientific in a research note on Thursday, December 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, Boston Scientific presently has an average rating of “Buy” and a consensus target price of $125.21.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.